GlassScriptPhysician profile
Bennyka B Vessel
NPI 1821409848
$2,522.61
in general payments reported to CMS, 2019-2025
20 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $319 · 2024: $986 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,522.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $506.97 | 2023-2025 | Mounjaro, Zepbound |
| Amgen INC. | $257.80 | 2024-2025 | Krystexxa |
| Phathom Pharmaceuticals, INC. | $250.29 | 2024-2025 | Voquezna |
| Dexcom, INC. | $150.00 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Janssen Biotech, INC. | $146.19 | 2025 | |
| Abbvie INC. | $123.25 | 2024 | |
| Neurelis, INC. | $121.33 | 2024 | Valtoco |
| Kyowa Kirin, INC. | $118.37 | 2025 | |
| Abbott Laboratories | $115.09 | 2023 | Freestyle Libre 3 |
| Neurocrine Biosciences, INC. | $103.72 | 2025 | |
| Sage Therapeutics, LLC | $100.00 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $97.46 | 2024 | |
| Edwards Lifesciences Corporation | $87.73 | 2025 | |
| Janssen Pharmaceuticals, INC | $85.43 | 2025 | Spravato |
| Viiv Healthcare Company | $84.57 | 2023-2025 | Apretude |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $62.96 | 2023 | |
| Medtronic, INC. | $54.25 | 2024 | Interstim |
| Emd Serono, INC. | $20.50 | 2024 | |
| Pfizer INC. | $18.56 | 2025 | |
| Gilead Sciences, INC. | $18.14 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bennyka Vessel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.